ARYVX Stock - American Century Global Real Estate Fd Inv Cl
Unlock GoAI Insights for ARYVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $176.19B | $158.06B | $136.34B | $127.14B | $155.90B |
| Gross Profit | $16.16B | $17.21B | $16.44B | $6.01B | $12.88B |
| Gross Margin | 9.2% | 10.9% | 12.1% | 4.7% | 8.3% |
| Operating Income | $5.36B | $8.07B | $6.72B | $-4,115,000,000 | $113.00M |
| Net Income | $4.35B | $-1,981,000,000 | $17.94B | $-1,279,000,000 | $47.00M |
| Net Margin | 2.5% | -1.3% | 13.2% | -1.0% | 0.0% |
| EPS | $1.08 | $-0.49 | $4.45 | $-0.32 | $0.01 |
The investment seeks high total investment return through a combination of capital appreciation and current income. The fund invests at least 80% of its net assets in equity securities issued by real estate investment trusts (REITs) and other companies engaged in the real estate industry (collectively, real estate securities). It invests primarily in equity securities of companies located in developed countries world-wide (including the United States), but may also invest in emerging markets. Normally, the fund will invest at least 30% of its assets in securities of issuers located outside the United States.
Earnings History & Surprises
ARYVXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Dec 31, 2023 | — | $-0.13 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.30 | — | — |
Latest News
Frequently Asked Questions about ARYVX
What is ARYVX's current stock price?
What is the analyst price target for ARYVX?
What sector is American Century Global Real Estate Fd Inv Cl in?
What is ARYVX's market cap?
Does ARYVX pay dividends?
Similar Stocks
Financial Services SectorExplore stocks similar to ARYVX for comparison